{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:03Z","timestamp":1793305983077,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017001","name":"University of Alberta Li Ka Shing Institute of Virology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["481194"],"award-info":[{"award-number":["481194"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104824","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:51:25Z","timestamp":1791183085000},"page":"104824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New insights into FOX proteins in cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Sara","family":"AlRawashdeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gazia","family":"Buzaakuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghd","family":"Obidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Karpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-1835","authenticated-orcid":false,"given":"Carlos A.","family":"Vel\u00e1zquez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104824_b0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tig.2011.03.003","article-title":"Forkhead transcription factors: key players in health and disease","volume":"27","author":"Benayoun","year":"2011","journal-title":"Trends Genet"},{"key":"10.1016\/j.drudis.2026.104824_b0010","doi-asserted-by":"crossref","first-page":"10235","DOI":"10.1093\/nar\/gkab807","article-title":"Toward a mechanistic understanding of DNA binding by forkhead transcription factors and its perturbation by pathogenic mutations","volume":"49","author":"Dai","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104824_b0015","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1242\/dev.112672","article-title":"Kaestner KH Fox transcription factors: from development to disease","volume":"143","author":"Golson","year":"2016","journal-title":"Development"},{"key":"10.1016\/j.drudis.2026.104824_b0020","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1021\/acs.biochem.7b00211","article-title":"Structure of the forkhead domain of FOXA2 bound to a complete DNA consensus site","volume":"56","author":"Li","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104824_b0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41420-024-01936-1","article-title":"FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104824_b0030","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46131","article-title":"An order-to-disorder structural switch activates the FoxM1 transcription factor","volume":"8","author":"Marceau","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104824_b0035","doi-asserted-by":"crossref","first-page":"11096","DOI":"10.1021\/acs.jcim.6c01772","article-title":"Ser715 phosphorylation induces \u03b2-hairpin unfolding and destabilization of FOXM1 autoinhibition","volume":"66","author":"AlRawashdeh","year":"2026","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.drudis.2026.104824_b0040","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrc3539","article-title":"Forkhead box proteins: tuning forks for transcriptional harmony","volume":"13","author":"Lam","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104824_b0045","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/0008-5472.CAN-21-3371","article-title":"Forkhead box transcription factors: double-edged swords in cancer","volume":"82","author":"Castaneda","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0050","doi-asserted-by":"crossref","first-page":"17098","DOI":"10.1021\/acs.jmedchem.1c01069","article-title":"Targeting of the FOXM1 oncoprotein by E3 ligase-assisted degradation","volume":"64","author":"Luo","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2026.104824_b0055","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104824_b0060","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1016\/j.molcel.2024.09.024","article-title":"Redirecting the pioneering function of FOXA1 with covalent small molecules","volume":"84","author":"Won","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2026.104824_b0065","article-title":"Joint sequence & chromatin neural networks characterize the differential abilities of Forkhead transcription factors to engage inaccessible chromatin","author":"Arora","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2026.104824_b0070","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41419-023-06177-1","article-title":"FOXO family isoforms","volume":"14","author":"Santos","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104824_b0075","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.semcancer.2017.07.007","article-title":"Role of Forkhead Box Class O proteins in cancer progression and metastasis","volume":"50","author":"Kim","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0080","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00018-015-2112-y","article-title":"FOXO transcription factors in cancer development and therapy","volume":"73","author":"de Brach\u00e8ne","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2026.104824_b0085","first-page":"4351","article-title":"Upregulated forkhead-box A3 elevates the expression of forkhead-box A1 and forkhead-box A2 to promote metastasis in esophageal cancer","volume":"17","author":"Chen","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2026.104824_b0090","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/ijms21051796","article-title":"Opposing roles of FoxA1 and FoxA3 in intrahepatic cholangiocarcinoma progression","volume":"21","author":"Thanan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104824_b0095","doi-asserted-by":"crossref","first-page":"22189","DOI":"10.1073\/pnas.1906484116","article-title":"Wnt activator FOXB2 drives the neuroendocrine differentiation of prostate cancer","volume":"116","author":"Moparthi","year":"2019","journal-title":"Proc Nat Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104824_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.721959","article-title":"Therapeutically targeting cancers that overexpress FOXC1: a transcriptional driver of cell plasticity, partial EMT, and cancer metastasis","volume":"11","author":"Ray","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2026.104824_b0105","first-page":"92","article-title":"Unravelling the therapeutic potential of forkhead box proteins in breast cancer: an update (review)","volume":"52","author":"Anwar","year":"2024","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2026.104824_b0110","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231155284","article-title":"The FOXC2 transcription factor: a master regulator of chemoresistance in cancer","volume":"22","author":"Hargadon","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.drudis.2026.104824_b0115","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OTT.S241367","article-title":"FOXC2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via MAPK\/ERK signaling in colorectal cancer","volume":"13","author":"Chen","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2026.104824_b0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2022.07.009","article-title":"Dysregulated FOXM1 signaling in the regulation of cancer stem cells","volume":"86","author":"Sher","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.03.007","article-title":"FOXM1: a small fox that makes more tracks for cancer progression and metastasis","volume":"92","author":"Khan","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0130","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.21037\/atm-21-5271","article-title":"A narrative review of research progress on FoxM1 in breast cancer carcinogenesis and therapeutics","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.drudis.2026.104824_b0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-024-06713-7","article-title":"FOXP4-mediated induction of PTK7 activates the Wnt\/\u03b2-catenin pathway and promotes ovarian cancer development","volume":"15","author":"Ji","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104824_b0140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s42003-024-06433-w","article-title":"Androgen-responsive FOXP4 is a target for endometrial carcinoma","volume":"7","author":"Kayahashi","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0145","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.2147\/CMAR.S191641","article-title":"Upregulation of FOXP4 in breast cancer promotes migration and invasion through facilitating EMT","volume":"11","author":"Ma","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.drudis.2026.104824_b0150","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1158\/0008-5472.CAN-22-0671","article-title":"FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits","volume":"82","author":"Tsai","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0155","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1158\/1078-0432.CCR-24-3471","article-title":"Structurally oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107209","article-title":"FOXO1 promotes cancer cell growth through MDM2-mediated p53 degradation","volume":"300","author":"Tomiyasu","year":"2024","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104824_b0165","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood-2018-06-856203","article-title":"Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells","volume":"132","author":"Kabrani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104824_b0170","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.immuni.2021.07.009","article-title":"Mutations in the transcription factor FOXO1 mimic positive selection signals to promote germinal center B cell expansion and lymphomagenesis","volume":"54","author":"Roberto","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2026.104824_b0175","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.4251\/wjgo.v13.i10.1367","article-title":"Diverse roles of FOXO family members in gastric cancer","volume":"13","author":"Chen","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.drudis.2026.104824_b0180","first-page":"322","article-title":"FOXP3 as an X-linked tumor suppressor","volume":"10","author":"Wang","year":"2010","journal-title":"Discov Med"},{"key":"10.1016\/j.drudis.2026.104824_b0185","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-10-3268","article-title":"Identification of a tumor suppressor relay between the FOXP3 and the Hippo pathways in breast and prostate cancers","volume":"71","author":"Li","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116324","article-title":"Targeting FOXA1 and FOXA2 disrupts the lineage-specific oncogenic output program in prostate cancer","volume":"44","author":"Formaggio","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104824_b0195","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2018.01.004","article-title":"FoxO transcription factors in cancer metabolism","volume":"50","author":"Yadav","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0200","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3390\/cells9071586","article-title":"Role of FOXO transcription factors in cancer metabolism and angiogenesis","volume":"9","author":"Farhan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104824_b0205","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/acscentsci.2c01449","article-title":"A systematic approach to the discovery of protein-protein interaction stabilizers","volume":"9","author":"Kenanova","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2026.104824_b0210","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr7934","article-title":"CD4+FOXP3Exon2+ regulatory T cell frequency predicts breast cancer prognosis and survival","volume":"11","author":"Fusco","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2026.104824_b0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/ITT.S55415","article-title":"The role of regulatory T cells in cancer immunology","volume":"4","author":"Whiteside","year":"2015","journal-title":"ImmunoTargets Ther"},{"key":"10.1016\/j.drudis.2026.104824_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114871","article-title":"Stimulation of antitumor immunity by FoxP3-targeting PROTAC","volume":"163","author":"Wang","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2026.104824_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129945","article-title":"Discovery of a proteolysis targeting chimera (PROTAC) as a potent regulator of FOXP3","volume":"112","author":"Yang","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104824_b0230","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.18632\/oncotarget.6510","article-title":"FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells","volume":"7","author":"Choi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104824_b0235","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s43587-024-00607-1","article-title":"Spatiotemporal transcriptomic changes of human ovarian aging and the regulatory role of FOXP1","volume":"4","author":"Wu","year":"2024","journal-title":"Nat Aging"},{"key":"10.1016\/j.drudis.2026.104824_b0240","article-title":"Effect of FOXP2 transcription factor on immune infiltration of thyroid cancer and its potential clinical value","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2026.104824_b0245","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.937069","article-title":"FOXP family DNA methylation correlates with immune infiltration and prognostic value in NSCLC","volume":"13","author":"Hu","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.drudis.2026.104824_b0250","first-page":"3944","article-title":"Upregulation of FoxP4 in HCC promotes migration and invasion through regulation of EMT","volume":"17","author":"Zhang","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2026.104824_b0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/cancers11020251","article-title":"Pan-cancer analyses reveal genomic features of FOXM1 overexpression in cancer","volume":"11","author":"Barger","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104824_b0260","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.3390\/cancers13123065","article-title":"FOXM1: a multifunctional oncoprotein and emerging therapeutic target in ovarian cancer","volume":"13","author":"Liu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104824_b0265","article-title":"FoxM1 promotes stemness and radio-resistance of glioblastoma by regulating the master stem cell regulator Sox2","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104824_b0270","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/s41419-024-06767-7","article-title":"Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness","volume":"15","author":"Battistini","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104824_b0275","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.3390\/cancers16223823","article-title":"Therapeutic landscape of FOXM1 in triple-negative breast cancer and aggressive solid cancers","volume":"16","author":"Dilmac","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104824_b0280","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1158\/0008-5472.CAN-16-3566","article-title":"FOXM1 in cancer: interactions and vulnerabilities","volume":"77","author":"Gartel","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41420-024-01929-0","article-title":"Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies","volume":"10","author":"Raghuwanshi","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2026.104824_b0290","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.53","article-title":"The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells","volume":"8","author":"Hou","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2026.104824_b0295","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/B978-0-12-407190-2.00016-2","article-title":"FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy","volume":"119","author":"Wierstra","year":"2013","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031761","article-title":"Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage","volume":"7","author":"Halasi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104824_b0305","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1038\/s41388-024-03117-x","article-title":"RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer","volume":"43","author":"Jirapongwattana","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2026.104824_b0310","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55070","article-title":"Co-regulation and function of FOXM1\/ RHNO1 bidirectional genes in cancer","volume":"10","author":"Barger","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2026.104824_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104667","article-title":"FOX transcription factors are common regulators of Wnt\/\u03b2-catenin-dependent gene transcription","volume":"299","author":"Moparthi","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104824_b0320","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.drudis.2026.104824_b0325","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1038\/s41467-026-69556-0","article-title":"FOXJ1 mediates taxane resistance through regulation of microtubule dynamics","volume":"17","author":"Xie","year":"2026","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104824_b0330","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1038\/s44321-026-00476-8","article-title":"Foxs1-mediated transformation of CD34+ fibroblast to myCAFs promotes tumor growth","volume":"18","author":"Yang","year":"2026","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2026.104824_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189015","article-title":"Small-molecule inhibitors targeting FOXM1: current challenges and future perspectives in cancer treatments","volume":"1878","author":"Raghuwanshi","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104824_b0340","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1021\/bi0602718","article-title":"Intrinsic disorder in transcription factors","volume":"45","author":"Liu","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104824_b0345","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nrm3920","article-title":"Intrinsically disordered proteins in cellular signalling and regulation","volume":"16","author":"Wright","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0350","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-0716-2815-7_9","article-title":"Targeting transcription factors in cancer: from \u2018undruggable\u2019 to \u2018druggable\u2019","volume":"2594","author":"Tao","year":"2023","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2026.104824_b0355","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41586-024-08421-w","article-title":"Targeting FOXM1 condensates reduces breast tumour growth and metastasis","volume":"638","author":"Xie","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104824_b0360","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104824_b0365","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s11030-022-10519-0","article-title":"Homology modeling of Forkhead box protein C2: identification of potential inhibitors using ligand and structure-based virtual screening","volume":"27","author":"Ibrahim","year":"2023","journal-title":"Mol Divers"},{"key":"10.1016\/j.drudis.2026.104824_b0370","doi-asserted-by":"crossref","first-page":"7708","DOI":"10.1007\/s12010-023-04490-1","article-title":"Homology modeling, screening, and identification of potential FOXO6 inhibitors curtail gastric cancer progression: an in silico drug repurposing approach","volume":"195","author":"Poleboyina","year":"2023","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.drudis.2026.104824_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1058256","article-title":"Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer","volume":"10","author":"Zhou","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.drudis.2026.104824_b0380","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12032-024-02427-0","article-title":"A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells","volume":"41","author":"Abusharkh","year":"2024","journal-title":"Med Oncol"},{"key":"10.1016\/j.drudis.2026.104824_b0385","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/biom11060856","article-title":"Molecular dynamics simulations of human FOXO3 reveal intrinsically disordered regions spread spatially by intramolecular electrostatic repulsion","volume":"11","author":"Weinzierl","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2026.104824_b0390","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1038\/ncomms6165","article-title":"Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition","volume":"5","author":"Gormally","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104824_b0395","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-019-0141-7","article-title":"Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds","volume":"5","author":"Ziegler","year":"2019","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104824_b0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13048-024-01421-4","article-title":"NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells","volume":"17","author":"Liu","year":"2024","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.drudis.2026.104824_b0405","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/bloodadvances.2024015560","article-title":"Beyond FOXO1: AS1842856 inhibits GSK3 to enhance cytotoxic effects in B-ALL","volume":"9","author":"Ketzer","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2026.104824_b0410","doi-asserted-by":"crossref","first-page":"40323","DOI":"10.1021\/acsomega.6c02787","article-title":"Repurposing masitinib mesylate as a novel FOXM1 inhibitor for the treatment of aggressive solid tumors: preclinical validation in human breast and oral cancer cells and organotypic tumor slice culture","volume":"11","author":"Gupta","year":"2026","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104824_b0415","doi-asserted-by":"crossref","first-page":"13497","DOI":"10.3390\/ijms241713497","article-title":"Application of novel transcription factor machine learning model and targeted drug combination therapy strategy in triple negative breast cancer","volume":"24","author":"Pang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104824_b0420","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","article-title":"Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108626","article-title":"A novel designed fully peptide-based PROTAC, FPP29, demonstrates its potent cytotoxic effects to liver cancer HCCLM3 cells by targeting FOXM1","volume":"163","author":"Jia","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2026.104824_b0430","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1021\/acs.molpharmaceut.5c00219","article-title":"Self-assembled peptide PROTAC prodrugs targeting FOXM1 for cancer therapy","volume":"22","author":"Zeng","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104824_b0435","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.7150\/thno.129569","article-title":"A peptide-based PROTAC targeting FOXM1 suppresses fibrosis-associated hepatocarcinogenesis","volume":"16","author":"Wu","year":"2026","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2026.104824_b0440","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.3390\/cancers18152375","article-title":"PAX3::FOXO1-targeting PROTAC induces myogenic differentiation of fusion-positive Rhabdomyosarcoma cells","volume":"18","author":"Knoll","year":"2026","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104824_b0445","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3390\/cancers17111871","article-title":"Targeting the undruggable: recent progress in PROTAC-induced transcription factor degradation","volume":"17","author":"Jung","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2026.104824_b0450","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abn2707","article-title":"The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells","volume":"15","author":"Kurimchak","year":"2022","journal-title":"Sci Signal"},{"key":"10.1016\/j.drudis.2026.104824_b0455","article-title":"Predicting PROTAC-targeted degradation and designing androgen receptor degraders with AiPROTAC","author":"Zhang","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.drudis.2026.104824_b0460","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae358","article-title":"DiffPROTACs is a deep learning-based generator for proteolysis targeting chimeras","volume":"25","author":"Li","year":"2024","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2026.104824_b0465","doi-asserted-by":"crossref","first-page":"D1510","DOI":"10.1093\/nar\/gkae768","article-title":"PROTAC-DB 3.0: an updated database of PROTACs with extended pharmacokinetic parameters","volume":"53","author":"Ge","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.drudis.2026.104824_b0470","doi-asserted-by":"crossref","first-page":"815","DOI":"10.7150\/ijbs.20052","article-title":"FOXO signaling pathways as therapeutic targets in cancer","volume":"13","author":"Farhan","year":"2017","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2026.104824_b0475","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13046-023-02872-1","article-title":"Invasive FoxM1 phosphorylated by PLK1 induces the polarization of tumor-associated macrophages to promote immune escape and metastasis, amplified by IFITM1","volume":"42","author":"Xu","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2026.104824_b0480","doi-asserted-by":"crossref","first-page":"e00224","DOI":"10.1128\/MCB.00224-20","article-title":"Genome-wide analysis of the FOXA1 transcriptional network identifies novel protein-coding and long noncoding RNA targets in colorectal cancer cells","volume":"40","author":"Lazar","year":"2020","journal-title":"Mol Cell Biol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:22Z","timestamp":1793305282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002291"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104824","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into FOX proteins in cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104824"}}